**1st Quarter 2023 Report (January 1 – March 31)**

Percent change evaluated relative to 1st Quarter 2022

Summary

- The percentage of prescribers enrolled in the PDMP system has stayed consistent compared to the 1st quarter of 2022 (*Figure 1* and *Table 1*).
- Total Gateway automated queries and reports viewed have decreased, while web queries have increased from the 1st quarter of 2022 (*Table 3*).
- Overall, the total number of prescriptions for controlled substances have increased (2.4%) since the 1st quarter of 2022. Gabapentin is the most prescribed substance in the system with a slight increase (+2.7%) in prescriptions over Q1 2022. Stimulant prescriptions continue to increase with amphetamine prescriptions up 3.0% and methylphenidate prescriptions increasing 15.8% (*Table 4*).

Figure 1. Oregon PDMP Registration: 2013-2023

- *Figure 1* shows the percentage of PDMP-enrolled prescribers over time from 2013-2022. Registration has remained high since 2018, especially among top prescribers.

(Note: Report updated December 2024 to reflect more accurate automated query counts.)

Oregon Prescription Drug Monitoring Program

healthoregon.org/pdmp

Table 1. PDMP Enrollment and System Use for Oregon Prescribers[1]: Jan. 1 – March 31, 2023.

User Type	Prescribers	Enrolled	Web Query	Automated Query	Total Query
All Prescribers (by DEA)	19,116	16,352 / 85.5%	3,825 / 23.4%	12,549 / 76.7%	13,312 / 81.4%
Top 4,000 Prescribers	4,000	3,904 / 97.6%	1,708 / 43.8%	3,520 / 90.2%	3,693 / 94.6%
Top 2,000 Prescribers	2,000	1,972 / 98.6%	975 / 49.4%	1,807 / 91.6%	1,892 / 95.9%

[1]Counts provided by unique DEA number, but providers may have multiple DEA numbers.

- Controlled substances were prescribed by 19,116 Oregon providers in Q1 of 2023.
- During the 1st quarter, 81.4% of enrolled prescribers, 94.6% of the top 4,000 prescribers, and 95.9% of the top 2,000 prescribers used the web portal or integration.
- The percentage of enrolled prescribers querying the PDMP has slightly decreased since the 1st quarter of 2022, when 83.9% of enrolled prescribers submitted queries.

Table 2. Special Requests: January 1 - March 31, 2023.

Measure	Count
Patient Records	8
Healthcare Boards	33
Law Enforcement	14
Total Special Requests	**55**

- 55 special requests were received and processed by PDMP staff.
- Healthcare boards continue to be the most frequent originators of these requests.

(Note: Report updated December 2024 to reflect more accurate automated query counts.)

Table 3. PDMP Queries Summary Statistics: January 1– March 31, 2023.

User Type	Web Portal		Gateway Integration			
	Queries[1]	% Change[2]	Automated Queries[1]	% Change[2]	Reports Viewed[1]	% Change[2]
Healthcare providers	87,179	-1.6%	5,399,612	-10.0%	744,207	-26.5%
Pharmacies	100,988	43.1%	1,203,044	4.5%	637,618	10.1%
Delegates	156,452	0.1%	NA	NA	NA	NA
Total Queries[2]	**344,747**	**9.3%**	**6,602,666**	**-7.7%**	**1,381,829**	**-13.2%**

[1]Query data drawn from AWARxE web portal, PMPi Gateway audit file and EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID, and query date.
[2]Percent change evaluated relative to same quarter the prior year.

- Total web portal queries have increased from the same quarter last year, with the largest increase seen in queries by pharmacies. Healthcare providers usage of the web portal slightly decreased (-1.6%) compared to the 1st quarter of 2022.
- The total number of Gateway electronic health record (EHR)-integrated automated queries and reports viewed has decreased over the same quarter last year.

Table 4. Query by Clinical User Group for Enrolled Providers: January 1– March 31, 2023.

Discipline	Total Accounts (by DEA)[1]	% Change[2]	Web User[3]	% Change[2]	Integrated User[3]	% Change[2]
MD/PA/DO	19,541	9.8%	1,702	0.9%	15,084	9.8%
NP/CNS-PP	4,666	4.8%	1,096	10.5%	3,508	6.5%
RPh	3,183	-2.4%	1,322	-5.2%	419	-0.9%
Delegates	3,158	-3.3%	1,698	0.1%	NA	NA
DDS/DMD	2,675	-2.1%	388	-3.7%	268	13.1%
ND	544	-11.3%	180	22.4%	446	-0.9%

[1]Counts provided by unique DEA Number, but providers may be associated with multiple DEA numbers.
[2]Percent change evaluated relative to same quarter during the prior year.
[3]Query data drawn from Appriss AWARxE web portal, PMPi Gateway audit file and EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID, and date of query.

- Integrated Gateway usage continues to be popular among all clinical user groups, especially with MD/PA/DO and NP/CNS-PP disciplines.

(Note: Report updated December 2024 to reflect more accurate automated query counts.)

Table 5. Top Prescriptions: January 1– March 31, 2023.

Drug	Number of Rx	% of all Rx	% Change
All	1,646,051	100%	2.4%
Gabapentin	233,688	14.2%	2.7%
Oxycodone	223,304	13.6%	3.5%
Hydrocodone	213,482	13.0%	-3.6%
Amphetamine	197,703	12.0%	3.0%
Methylphenidate	94,300	5.7%	15.8%
Lorazepam	82,159	5.0%	1.1%
Tramadol	74,668	4.5%	-2.0%
Zolpidem	60,786	3.7%	-3.7%
Alprazolam	57,611	3.5%	-2.5%
Clonazepam	55,578	3.4%	-3.2%

- Prescriptions increased 2.4% relative to the 1st quarter of 2022 with Gabapentin as the top prescribed drug in the PDMP (14.2% of all prescriptions). The addition of gabapentin as a PDMP covered substance was effective as of January 1st, 2020.
- Prescriptions for the stimulants, amphetamine and methylphenidate, increased by 3.0% and 15.8% relative to the same quarter last year.

Table 6. Prescriptions for Buprenorphine and Naloxone: January 1– March 31, 2023.

Drug	Number of Rx	% of all Rx	% Change
Buprenorphine/Naloxone	42,612	2.6%	-1.0%
Buprenorphine	24,774	1.5%	9.2%
Naloxone	10,511	0.6%	75.2%

- Prescriptions for buprenorphine and naloxone increased while buprenorphine/naloxone combinations slightly decreased. Naloxone prescriptions will not be collected by the PDMP starting Fall 2023.

Contact: PDMP Research Analyst, pdmp.research@odhsoha.oregon.gov

(Note: Report updated December 2024 to reflect more accurate automated query counts.)